Great Point Partners LLC Has $10.21 Million Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Great Point Partners LLC decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL) by 18.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,811,955 shares of the company’s stock after selling 629,712 shares during the period. Autolus Therapeutics accounts for about 3.0% of Great Point Partners LLC’s holdings, making the stock its 15th biggest holding. Great Point Partners LLC owned 1.06% of Autolus Therapeutics worth $10,207,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AUTL. Price T Rowe Associates Inc. MD raised its stake in Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the last quarter. Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics in the 1st quarter valued at about $100,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Autolus Therapeutics in the 1st quarter valued at about $108,000. Cetera Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at about $839,000. Finally, SG Americas Securities LLC grew its stake in Autolus Therapeutics by 853.2% during the second quarter. SG Americas Securities LLC now owns 189,240 shares of the company’s stock worth $659,000 after purchasing an additional 169,387 shares during the period. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Trading Up 4.0 %

AUTL opened at $3.10 on Wednesday. The company’s fifty day moving average price is $3.77 and its two-hundred day moving average price is $3.93. The company has a market cap of $824.88 million, a price-to-earnings ratio of -2.46 and a beta of 2.04. Autolus Therapeutics plc has a 1-year low of $2.69 and a 1-year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the firm earned ($0.26) earnings per share. As a group, equities analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on AUTL shares. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.15.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.